Top Markets
#1 Ontology Gas Ontology Gas +31.11%
#2 Verus Coin Verus Coin +22.50%
#3 Status Status +21.81%
#4 Bitway Bitway +15.86%
#5 ETHGas ETHGas +15.11%
#6 Geodnet Geodnet +14.89%
#7 The Black Bull The Black Bull +11.57%
#8 Derive Derive +11.47%
#9 Curve DAO Curve DAO +11.06%
#10 Fake World Assets Fake World Assets +10.89%
Coin of the day
Ontology Gas Ontology Gas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
ATyr Pharma, Inc. ATyr Pharma, Inc.

ATyr Pharma, Inc.

ATYR
Clasificación en acciones #25448
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego,... aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Precio por acción
$0.5049
Última sincronización: 2026-08-20
Capitalización bursátil
$49.51M
Cambio (1 día)
-5.24%
Cambio (1 año)
-89.80%
País
US
Comercio ATyr Pharma, Inc. (ATYR)

Categoría

Healthcare
Ganancias de ATyr Pharma, Inc. (ATYR)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di ATyr Pharma, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de ATyr Pharma, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US